Search - tctmd.com

Displaying 1 - 20 of 204

Sort: Relevancy | Date

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

Todd Neale

November 09, 2025

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2025

Caitlin E. Cox

April 30, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Opinion CV Team Dispatch

February 2025 Dispatch for the CV Team

L.A. McKeown

February 01, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Shelley Wood

November 14, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

Shelley Wood

January 17, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2023

Shelley Wood

November 30, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Daily News

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

Yael L. Maxwell

October 09, 2023

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2023

Shelley Wood

October 03, 2023

News Daily News

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

L.A. McKeown

August 31, 2023

News Daily News

Top Coronary Artery Disease News of 2022

Yael L. Maxwell

December 29, 2022

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

Todd Neale

September 21, 2022

Presentation TCT 2022

Prevention of Radial Artery Occlusion With Rivaroxaban After Transradial Coronary Procedures: The RIVARAD Multicentric Randomized Trial

Presenter: Rania Hammami

September 19, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2022

Shelley Wood

September 01, 2022

Advertisement

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

What’s Going to Be Hot at AHA 2025?

TCTMD’s Top 10 Most Popular Stories for April 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

What’s Going to Be Hot at ACC 2025?

February 2025 Dispatch for the CV Team

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

CMS Announces Negotiated Medicare Prices for First 10 Drugs

DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

TCTMD’s Top 10 Most Popular Stories for November 2023

What’s Going to Be Hot at AHA 2023

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

TCTMD’s Top 10 Most Popular Stories for September 2023

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

Top Coronary Artery Disease News of 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

Prevention of Radial Artery Occlusion With Rivaroxaban After Transradial Coronary Procedures: The RIVARAD Multicentric Randomized Trial

TCTMD’s Top 10 Most Popular Stories for August 2022

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content